Patents by Inventor Volker BADOCK
Volker BADOCK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220227729Abstract: The present invention relates to compounds of formula (1) in which A, U and R1 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant KRAS signaling, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 14, 2020Publication date: July 21, 2022Applicant: Bayer AktiengesellschaftInventors: Duy NGUYEN, Knut EIS, Jeremie Xavier MORTIER, Hans BRIEM, Clara CHRIST, Anders Roland FRIBERG, Benjamin BADER, Patrick STEIGEMANN, Volker BADOCK, Jens SCHRÖDER, Franziska SIEGEL, Dieter MOOSMAYER
-
Patent number: 10722501Abstract: The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.Type: GrantFiled: May 8, 2017Date of Patent: July 28, 2020Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Nicole Biber, Damian Brockschnieder, Kersten Matthias Gericke, Florian Kölling, Klemens Lustig, Jörg Meding, Heinrich Meier, Thomas Neubauer, Martina Schäfer, Andreas Timmermann, Dmitry Zubov, Carsten Terjung, Niels Lindner, Volker Badock, Dieter Moosmayer, Hideki Miyatake Ondozabal, Stephen Moore, Alexander Schulz
-
Publication number: 20190160048Abstract: The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.Type: ApplicationFiled: May 8, 2017Publication date: May 30, 2019Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Nicole BIBER, Damian BROCKSCHNIEDER, Kersten Matthias GERICKE, Florian KÖLLING, Klemens LUSTIG, Jörg MEDING, Heinrich MEIER, Thomas NEUBAUER, Martina SCHÄFER, Andreas TIMMERMANN, Dmitry ZUBOV, Carsten TERJUNG, Niels LINDNER, Volker BADOCK, Dieter MOOSMAYER, Hideki MIYATAKE ONDOZABAL, Steven MOORE, Alexander SCHULZ
-
Patent number: 10023539Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R1, R2, R3, R4, R5, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumor disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.Type: GrantFiled: December 8, 2015Date of Patent: July 17, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Jeffrey Stuart Mowat, Timo Stellfeld, Carlo Stresemann, Roman Hillig, Silke Köhr, Detlef Stöckigt, Jörg Weiske, Thomas Brumby, Naomi Barak, Clara Christ, Antonius Ter Laak, Volker Badock, Rosemary Helen Crampton, Ian Stefanuti
-
Publication number: 20180118722Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I), wherein R1, R3, R4, R5 and n have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.Type: ApplicationFiled: April 14, 2016Publication date: May 3, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Timo STELLFELD, Carlo STRESEMANN, Roman HILLIG, Silke KÖHR, Detlef STÖCKIGT, Jörg WEISKE, Naomi BARAK, Clara CHRIST, Antonius TER LAAK, Volker BADOCK
-
Publication number: 20180099937Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine- pyrazolines of general formula (I), wherein R1, R2, R3, R4 and R5 have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.Type: ApplicationFiled: April 14, 2016Publication date: April 12, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Timo STELLFELD, Jeffrey Stuart MOWAT, Carlo STRESEMANN, Roman HILLIG, Silke KÖHR, Detlef STÖCKIGT, Jörg WEISKE, Ingo HARTUNG, Naomi BARAK, Clara CHRIST, Antonius TER LAAK, Volker BADOCK, Rosemary Helen CRAMPTON, Ian STEFANUTI
-
Publication number: 20170342034Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R1, R2, R3, R4, R5, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.Type: ApplicationFiled: December 8, 2015Publication date: November 30, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Jeffrey Stuart MOWAT, Timo STELLFELD, Carlo STRESEMANN, Roman HILLIG, Silke KÖHR, Detlef STÖCKIGT, Jörg WEISKE, Thomas BRUMBY, Naomi BARACK, Clara CHRIST, Antonius TER LAAK, Volker BADOCK, Rosemary Helen CRAMPTON, Ian STEFANUTI